about
Microfluidic assembly of multistage porous silicon-lipid vesicles for controlled drug releaseStabilizing Agents for Drug Nanocrystals: Effect on BioavailabilityMesoporous silica material TUD-1 as a drug delivery systemAmine-modified hyaluronic acid-functionalized porous silicon nanoparticles for targeting breast cancer tumors.Cell-polymer interactions of fluorescent polystyrene latex particles coated with thermosensitive poly(N-isopropylacrylamide) and poly(N-vinylcaprolactam) or grafted with poly(ethylene oxide)-macromonomer.Drug permeation across intestinal epithelial cells using porous silicon nanoparticles.Defining new criteria for selection of cell-based intestinal models using publicly available databases.Inhibitory activity of the isoflavone biochanin A on intracellular bacteria of genus Chlamydia and initial development of a buccal formulation.In vitro evaluation of biodegradable lignin-based nanoparticles for drug delivery and enhanced antiproliferation effect in cancer cells.Mesoporous silicon in drug delivery applications.Electrospraying, spray drying and related techniques for production and formulation of drug nanoparticles.Mesoporous materials and nanocrystals for enhancing the dissolution behavior of poorly water-soluble drugs.Porous silicon nanoparticles for nanomedicine: preparation and biomedical applications.Advanced Nanomedicines for the Treatment and Diagnosis of Myocardial Infarction and Heart Failure.Antihyperglycemic potential of incretins orally delivered via nano and microsystems and subsequent glucoregulatory effects.Safety and toxicity concerns of orally delivered nanoparticles as drug carriers.Microfluidics platform for glass capillaries and its application in droplet and nanoparticle fabrication.Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines.Drug-Loaded Multifunctional Nanoparticles Targeted to the Endocardial Layer of the Injured Heart Modulate Hypertrophic Signaling.Angiopep2-functionalized polymersomes for targeted doxorubicin delivery to glioblastoma cells.Drug permeation and cellular interaction of amino acid-coated drug combination powders for pulmonary delivery.Cyclodextrin-Modified Porous Silicon Nanoparticles for Efficient Sustained Drug Delivery and Proliferation Inhibition of Breast Cancer Cells.In vitro and in vivo assessment of heart-homing porous silicon nanoparticles.Multifunctional porous silicon nanoparticles for cancer theranostics.Delivery of therapeutics with nanoparticles: what's new in cancer immunotherapy?Dual-drug delivery by porous silicon nanoparticles for improved cellular uptake, sustained release, and combination therapy.Functionalization of alkyne-terminated thermally hydrocarbonized porous silicon nanoparticles with targeting peptides and antifouling polymers: effect on the human plasma protein adsorption.In vitro assessment of biopolymer-modified porous silicon microparticles for wound healing applications.In vivo evaluation of porous silicon and porous silicon solid lipid nanocomposites for passive targeting and imaging.Augmented cellular trafficking and endosomal escape of porous silicon nanoparticles via zwitterionic bilayer polymer surface engineering.Microparticles to enhance delivery of drugs and growth factors into wound sites.Brinzolamide nanocrystal formulations for ophthalmic delivery: reduction of elevated intraocular pressure in vivo.Poly(methyl vinyl ether-alt-maleic acid)-functionalized porous silicon nanoparticles for enhanced stability and cellular internalization.Copper-free azide-alkyne cycloaddition of targeting peptides to porous silicon nanoparticles for intracellular drug uptake.Tumour homing peptide-functionalized porous silicon nanovectors for cancer therapy.Co-delivery of a hydrophobic small molecule and a hydrophilic peptide by porous silicon nanoparticles.In vivo biocompatibility of porous silicon biomaterials for drug delivery to the heart.New times, new trends for ethionamide: In vitro evaluation of drug-loaded thermally carbonized porous silicon microparticles.Intravenous delivery of hydrophobin-functionalized porous silicon nanoparticles: stability, plasma protein adsorption and biodistribution.Spray-dried cellulose nanofibers as novel tablet excipient.
P50
Q26851133-5C79ED75-9542-450A-87B8-7FC7921C4A11Q28076633-FB047145-A6C8-4F3F-97C1-7F8DA376ED58Q28268800-8B1A21D3-C26B-468D-B068-CFAE9F5A35DAQ30425859-7216B78F-1005-4919-A89E-028300AA4659Q33285956-ABA650EA-0C97-4B66-9BDF-BC8F546534DEQ33782859-F6AA385E-E1AE-42B6-97A0-42C4DE3F30B8Q34314896-A115BDB6-C3C6-4207-82E0-4804F0976B7EQ34712836-08DE5EF9-3A63-4B0F-B1ED-9D7709E696C9Q36247961-D06F1958-CB31-4737-A133-0D587E55A156Q36839290-C575CB85-5AA1-47C8-9648-820E6686D7B0Q37719548-833DA95E-9953-424F-A027-97C99C85C402Q38174119-DE4AEFEE-6E30-44DB-831D-82B4E7C72865Q38208617-6BE6B9E1-5391-4347-A885-40E5C3ED3786Q38242104-1E682B66-A1FB-4902-8172-B6F1DC3BDE24Q38249004-2C05CC19-45EF-42D9-9B3E-74C95BF029E8Q38286203-F22681EB-5635-4E80-BDEF-72E1BBDE4BA1Q38375841-8A395B66-99F3-4F22-BFE7-CEB5E1C52F90Q38676164-8B1A7E40-3EF9-4FAF-8D50-738FE5415726Q38676235-39DF622F-63EC-4121-BABE-44B9381EA299Q38754197-AF0A67C6-29FD-468F-A130-AD8BA7A2260BQ38781972-695BAB73-32EB-4FD6-B760-C238101AF926Q38830004-99E65E38-3FD7-447C-8866-67161A51BBA2Q38877084-AC7FFEF9-D43D-400A-86BF-ED5F11B95BB0Q38907700-B62CF04E-2D67-4306-8459-BC82BDA4FD31Q38912004-FFB73D39-FA9E-4411-A29F-A71CD264E68AQ38914771-876012CA-42C6-49B4-A70D-9D2FCFFE7127Q38925549-CFB54FCA-8281-49A2-9C54-B1165AF85ED7Q38948845-FA92D830-8D60-489D-A793-94058032808BQ38979734-9D8E61E0-C2BB-4BD1-A690-209A4C8BBF65Q38987465-73282CA5-9958-4986-8B8E-3F8385A01BEFQ38993469-16A7D5B1-5B16-466A-AE92-AE9E1C7BC93EQ39010406-6F4738E4-11CC-4E0C-BF62-D3D557D3B3ADQ39027154-1E3AF1EC-B252-4F73-A725-6ED890198F7AQ39065346-A8C7F980-0A89-4491-9630-5E9725C7C0C3Q39099865-E1139013-AB43-4E70-B43C-BB90EBFA794CQ39140983-DB02F94A-C7F3-45C9-AE37-6A9856A68DB7Q39166414-D84A5152-674C-4889-9EE8-F5E76D8E23B1Q39379699-7B90DF53-1705-481E-B323-A53929B33790Q39406359-E371F12B-B252-4647-B388-17AB380E0C1CQ39422649-A7A93E18-3167-459D-A74D-8CF775896B3E
P50
description
researcher ORCID ID = 0000-0002-5029-1657
@en
wetenschapper
@nl
name
Jouni Hirvonen
@ast
Jouni Hirvonen
@en
Jouni Hirvonen
@es
Jouni Hirvonen
@nl
type
label
Jouni Hirvonen
@ast
Jouni Hirvonen
@en
Jouni Hirvonen
@es
Jouni Hirvonen
@nl
prefLabel
Jouni Hirvonen
@ast
Jouni Hirvonen
@en
Jouni Hirvonen
@es
Jouni Hirvonen
@nl
P31
P496
0000-0002-5029-1657